IntestiCult™ 类器官生长基础培养基 (人)

用于建立和维持人结直肠癌类器官的培养基

率先评论此产品

产品号 #（选择产品）

产品号 #100-0190_C

用于建立和维持人结直肠癌类器官的培养基

产品优势

使用生理相关的体外体系重现肿瘤特征及其异质性；
通过具有高度代表性的肿瘤类器官预测患者反应；
使用完整的培养基配方获得一致的实验结果；
借助易于操作的形式和优化的实验方案简化流程

要查看实验方案所需的所有配套产品，请参阅《实验方案与技术文档》。

总览

实验数据

产品说明书及文档

应用领域

总览

使用IntestiCult™ 类器官生长基础培养基 (人)高效培养不依赖 Wnt 的结直肠癌类器官。

肿瘤类器官作为一种体外系统具有较高的预测价值，因为它们保留了原发肿瘤的特征。使用IntestiCult™ 类器官生长基础培养基 (人)可为肿瘤类器官的生长和扩增提供最佳培养条件，同时保持肿瘤的异质性。该培养基不含 Wnt，可确保 Wnt 依赖的正常健康肠道细胞不会混入肿瘤类器官的培养。

使用IntestiCult™ 类器官生长基础培养基 (人)生成的肿瘤类器官适用于多种应用，包括模拟肿瘤发展，以及用于药物疗效和毒性的筛选。

关于培养健康的肠道类器官，请使用IntestiCult™ 类器官生长培养基 (人)或IntestiCult™-SF 类器官生长培养基 (人)。关于人肠道类器官的分化，请参考IntestiCult™ 类器官分化培养基 (人)。

欢迎通过我们的免费点播课程学习人肠类器官的培养方法，或浏览关于使用 IntestiCult™ 进行类器官培养流程的常见问题（FAQs）。此外，您还可以下载我们的电子书《Proven Protocols for Intestinal Organoid Culture: Getting Started with IntestiCult™》，获取肠类器官培养方案的精选合集。

细胞类型
癌细胞及细胞系，上皮细胞，肠道细胞

种属
人

应用
类器官培养

品牌
IntestiCult

研究领域
癌症，疾病建模，药物发现和毒理检测，上皮细胞研究，类器官

查看更多显示更少

实验数据

Figure 1. Growth of Cancer-Derived Organoids in IntestiCult™ OGM Human Basal Medium

Organoids were established from colorectal cancer biopsies in published medium1, then switched to IntestiCult™ OGMH (P0), as described below. Cancer-derived organoids demonstrated efficient growth both after establishment in IntestiCult™ OGM Human Basal Medium, as well as after passaging. Data used with permission from Hubrecht Organoid Technology.

Figure 2. IntestiCult™ OGM Human Basal Medium Enables Organoid Growth Across Different Patients

Organoids were established in published medium1 from colorectal tumor biopsy samples, then switched to IntestiCult™ OGM Human Basal Medium after passaging as described above. Organoids were passaged twice in IntestiCult™ OGMH Basal Medium and imaged at the end of the second passage (day 6 - 12). Data used with permission from Hubrecht Organoid Technology.

Confocal images of human colorectal cancer organoids stained with Ki67, EPCAM, and DAPI.

Figure 3. Colorectal Cancer Organoids Reflect Donor-Specific Colonic Features

Representative confocal images of human colorectal cancer organoids from four donors, cultured using IntestiCult™ OGM Human Basal Medium. Organoids were fixed and stained for Ki67 (green), EPCAM (red) and DAPI (Blue). Donor-specific differences in morphology were observed, including polarization and hollow lumens (A, B), or denser structures, lacking distinct epithelial polarization (C, D). Scale bars = 50 µm.

IC50 toxicity graphs demonstrating the response of colorectal cancer organoids to various cancer drugs.

Figure 4. Colorectal Cancer Organoids Cultured in IntestiCult™OGM Human Basal Medium Are Sensitive to Drug-Induced Toxicity in a Dose-Dependent Manner

Colorectal cancer organoids (CRCs) from 4 donors were treated with increasing concentrations of (A) 5-FU, (B) Flavopiridol, (C) Gefitinib, or (D) Irinotecan, and were compared to organoids from a healthy colon donor for 5 days. Cell viability was assessed on Day 7 using the CellTiter-Glo® Cell Viability Assay (Promega). Error bars = SEM.